Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics Inc (NQ: VRDN )

19.62 -0.17 (-0.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,341,975
Open 19.85
Bid (Size) 19.20 (1)
Ask (Size) 23.25 (1)
Prev. Close 19.79
Today's Range 19.46 - 20.41
52wk Range 11.40 - 27.20
Shares Outstanding 9,587,155
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics
Via Benzinga
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
From Viridian Therapeutics, Inc.
Via Business Wire

Performance

YTD
-12.21%
-12.21%
1 Month
-19.72%
-19.72%
3 Month
+27.90%
+27.90%
6 Month
+61.35%
+61.35%
1 Year
+25.13%
+25.13%

More News

Read More
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Analyst Expectations For Viridian Therapeutics's Future
Via Benzinga
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics
Via Benzinga
Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know
Via Benzinga
Decoding 6 Analyst Evaluations For Viridian Therapeutics
Via Benzinga
Expert Ratings For Viridian Therapeutics
Via Benzinga
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival
Via Investor's Business Daily
Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety
Via Benzinga
Exposures Product Safety
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Top 3 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Via Investor's Business Daily
3 Small-Cap Stocks With Explosive 2X Growth Potential
Via InvestorPlace
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.